Serotonin Syndrome and Behavioral Activation in Children and Adolescents
Diagnostic Criteria and Differentiation
- The American Academy of Child and Adolescent Psychiatry recommends assessing for true serotonin syndrome criteria, including mental status changes, neuromuscular hyperactivity, and autonomic hyperactivity, to differentiate it from behavioral activation 3
- Behavioral activation occurs early in treatment, improves quickly after SSRI dose decrease or discontinuation, and is more common in younger children with anxiety disorders, according to the American Academy of Child and Adolescent Psychiatry 1, 2, 5
- True serotonin syndrome typically requires a combination of serotonergic medications, presents with the full triad of symptoms, and symptoms arise within 24-48 hours after combining medications, as stated by the American Academy of Child and Adolescent Psychiatry 1, 2, 3, 4
Management of Behavioral Activation
- The American Academy of Child and Adolescent Psychiatry suggests reducing the fluvoxamine dose to 50mg daily or every other day and monitoring closely in cases of behavioral activation 1, 2
- Symptoms should improve within days of dose reduction, and continuing ERP therapy is critical, according to the American Academy of Child and Adolescent Psychiatry 1, 2
Management of True Serotonin Syndrome
- The American Academy of Child and Adolescent Psychiatry recommends immediate discontinuation of all serotonergic agents, hospital-based treatment with continuous cardiac monitoring, and supportive care, including benzodiazepines for agitation and cooling measures for hyperthermia, in cases of true serotonin syndrome 1, 2, 3, 4
Next Medication Strategy
- The American Academy of Child and Adolescent Psychiatry suggests considering alternative SSRIs, such as citalopram or escitalopram, with lower drug interaction profiles, or non-SSRI alternatives, such as buspirone, in cases of failed SSRIs 1, 3, 4, 6
- ERP therapy alone has demonstrated efficacy for OCD and anxiety disorders and may be preferable given medication intolerance history, according to the American Academy of Child and Adolescent Psychiatry and the American Family Physician 1, 6, 7
Critical Prescribing Considerations
- The American Academy of Child and Adolescent Psychiatry warns of fluvoxamine-specific risks, including discontinuation syndrome risk and extensive drug interaction potential via multiple CYP pathways 1, 3, 4, 6